AbCellera, Moderna to Identify Therapeutic Antibodies for mRNA Treatments
AbCellera and Moderna have teamed up in a multi-year effort to leverage AbCellera’s artificial intelligence-powered technology to identify therapeutic antibodies against up to six targets chosen by Moderna.
The deal grants Moderna the rights to develop and commercialize antibodies resulting from the collaboration, while AbCellera will get research payments as well as clinical and commercial milestone payments and royalties on net sales of products.
“Over the past year, Moderna has demonstrated the speed and impact of its mRNA vaccine technology in helping to protect people around the world,” said Carl Hansen, AbCellera’s CEO and president. “We are excited to work alongside their team to advance RNA-encoded antibodies as a new frontier in genetic medicines.”
The companies did not disclose financial details of the research and development deal.